You are here

P&T® Journal contents for July 2005

Features

Most published studies of IV PCA do not include the full range of costs associated with this therapy. The author reviews some of the important cost drivers.
Alex Macario, MD, MBA
Bisoprolol appears to have the potential to improve New York Heart Association class and exercise tolerance in patients with heart failure.
Maoqin Shu, MD, Ruixia Xi, PhD, Ping Zhang, MD, Guoxiang He, PhD, Zhiyuan Song, MD, Luxiang Chi, MD, and Guoqiang Zhuang, PhD
Meeting Highlights
The authors discuss recent findings on anastrozole for the treatment of localized breast cancer, trastuzumab for HER2-positive metastatic breast cancer, zolendronic acid and bone density in women with breast cancer, gemcitabine for non–small cell lung cancer, oblimersen sodium for advanced malignant melanoma, bevacizumab for recurrent ovarian cancer, standard therapy plus oxaliplatin for colorectal cancer, lenalidomide for myelodysplastic syndromes, and raloxifene for endometrial cancer.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Meeting Highlights
Mr. Alexander summarizes presentations on the relationship between paroxetine (Paxil®) and suicidal ideation, escitalopram (Lexapro®) for depression and comorbid anxiety, and a specialized form of methylphenidate HCl (OROS® MPH/Concerta®) for attention-deficit/hyperactivity disorder.
Walter Alexander, MS
Dr. Goldenberg reviews exenatide injection (Byetta™) for diabetes, pregabalin (Lyrica™) for partial-onset seizures in adults with epilepsy, and tigecycline (Tygacil™) for skin and intra-abdominal infections.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
David B. Nash, MD, MBA, describes the work performed at the University HealthSystem Consortium and the National Association of Public Hospitals in analyzing new biotechnology products.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses the incidence of life-threatening methemoglobinemia and its link with the use of topical anesthetic sprays containing benzocaine.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas comments on pressure from Congress to improve the FDA’s post-marketing surveillance of drugs for life-threatening illnesses.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Drs. Benjamin Chavez and Jose Rey review the benefits of eszopiclone (Lunesta™) for the treatment of insomnia.
Benjamin Chavez, PharmD, and Jose A. Rey, PharmD